Fig. 7.  Cox regression analysis of the association between the Blue_TNBC score and patient survival in HER2-Enriched breast cancer across 22 independent cohorts. Due to the limited number of ER-/HER2+ breast cancer cases in the cohorts tested, the predictive performance of Blue_TNBC for survival was instead evaluated in HER2-Enriched breast cancer. The HER2-Enriched subtype was defined using the R package genefu.